Search results
Showing 136 to 150 of 163 results for fibrosis
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
This evidence summary has been updated and replaced by NICE guideline NG78.
Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
This guidance has been updated and replaced by NICE technology appraisal guidance 988.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Discontinued Reference number: GID-TA10310
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
In development Reference number: GID-TA11372 Expected publication date: TBC
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections